Literature DB >> 25985018

Meta-Analysis of Distortion Product Otoacoustic Emission Retest Variability for Serial Monitoring of Cochlear Function in Adults.

Kelly M Reavis1, Garnett P McMillan, Marilyn F Dille, Dawn Konrad-Martin.   

Abstract

OBJECTIVE: Distortion product otoacoustic emissions (DPOAEs) have long been heralded as a means to objectively monitor cochlear function and increasingly are becoming a key component in hearing surveillance programs for individuals at risk for ototoxic- and occupational noise-related hearing loss. Yet clinicians are unsure how to define clinically meaningful shifts in DPOAE level. In this study, a meta-analysis approach is used to synthesize the DPOAE level test-retest literature to construct a set of DPOAE level shift reference limits that can be used clinically to define a statistically significant emission change.
DESIGN: The authors reviewed all published articles identified through a Medline search using the terms "Otoacoustic Emission Variability," "Otoacoustic Emission Reliability," "Otoacoustic Emission Repeatability," and "Otoacoustic Emission Test Retest" restricted to DPOAEs, adults, and English language. Articles with DPOAE level data elicited by moderate stimulus levels for f2 frequencies of 1000, 2000, 4000, or 6000 Hz were selected because these stimulus parameters were relatively well represented in the literature. The authors only included articles that reported the standard error of the measurement (SEM) or from which the SEM could be calculated. Meta-analysis was used to estimate the population mean SEM over the included studies. Models were fit separately for each f2 primary and included days since baseline and study-specific random effects.
RESULTS: Ten DPOAE test-retest studies met inclusion criteria for this meta-analysis. The SEM values varied widely across published studies (0.57 to 3.9 dB) and were provided for relatively short time intervals (less than 15 days on average). Time, or days since baseline, was statistically significant at higher f2 frequencies (4000 and 6000 Hz). From the model results, 90% reference limits specific to the f2 and elapsed time between baseline and follow-up measurements were established. Reference limits provided correspond to negative (emission decrement) and positive (emission enhancement) shifts indicative of the amount of measurement variability that, using this approach, must be tolerated as "normal" fluctuations over time. Changes larger than the reference limits are considered significant and warrant follow-up testing.
CONCLUSIONS: The meta-analysis presented provides reference limits that are appropriate for a set of specific f2 frequencies and time intervals. The meta-analysis concerns the SEM statistic directly, so that any preferred reference limit can be computed from the results and should be predicated upon the screening application. The presumed advantage of this meta-analytic approach is increased precision relative to limits suggested by any of the individual studies included in the analysis.

Entities:  

Mesh:

Year:  2015        PMID: 25985018      PMCID: PMC4632966          DOI: 10.1097/AUD.0000000000000176

Source DB:  PubMed          Journal:  Ear Hear        ISSN: 0196-0202            Impact factor:   3.570


  44 in total

1.  Immediate and short-term reliability of distortion-product otoacoustic emissions.

Authors:  Randall C Beattie; O T Kenworthy; Christina A Luna
Journal:  Int J Audiol       Date:  2003-09       Impact factor: 2.117

2.  Distortion product otoacoustic emissions: comparison of sequential versus simultaneous presentation of primary-tone pairs.

Authors:  Randall C Beattie
Journal:  J Am Acad Audiol       Date:  2003-11       Impact factor: 1.664

3.  Random-effects model for meta-analysis of clinical trials: an update.

Authors:  Rebecca DerSimonian; Raghu Kacker
Journal:  Contemp Clin Trials       Date:  2006-05-12       Impact factor: 2.226

4.  Low-level otoacoustic emissions may predict susceptibility to noise-induced hearing loss.

Authors:  Judi A Lapsley Miller; Lynne Marshall; Laurie M Heller; Linda M Hughes
Journal:  J Acoust Soc Am       Date:  2006-07       Impact factor: 1.840

5.  Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.

Authors:  Pelagia Stavroulaki; Ioannis C Vossinakis; Dimitra Dinopoulou; Spiros Doudounakis; George Adamopoulos; Nikolaos Apostolopoulos
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-02

6.  Drug-induced ototoxicity.

Authors:  R E Brummett
Journal:  Drugs       Date:  1980-06       Impact factor: 9.546

7.  Stimulated acoustic emissions from within the human auditory system.

Authors:  D T Kemp
Journal:  J Acoust Soc Am       Date:  1978-11       Impact factor: 1.840

8.  Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults.

Authors:  Laura Elizabeth Dreisbach; Kelly Melissa Long; Shannon Elizabeth Lees
Journal:  Ear Hear       Date:  2006-10       Impact factor: 3.570

Review 9.  Otoacoustic emissions.

Authors:  Brenda L Lonsbury-Martin; Glen K Martin
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2003-10       Impact factor: 2.064

10.  Temporary DPOAE level shifts, ABR threshold shifts and histopathological damage following below-critical-level noise exposures.

Authors:  Gary W Harding; Barbara A Bohne
Journal:  Hear Res       Date:  2004-10       Impact factor: 3.208

View more
  8 in total

1.  Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients.

Authors:  Débora Cristina de Oliveira Bezerra; Renata Oliveira de Barcelos; Ellen Carvalho de Castro; Claudia Cristina Jardim Duarte; Raquel de Vasconcellos Carvalhaes Oliveira; Tania Salgado de Sousa Torraca; Maria Helena de Araújo-Melo; Frederico Pereira Bom Braga; Benivaldo Ramos Ferreira Terceiro; Lúcia Regina do Nascimento Brahim Paes; Armando de Oliveira Schubach; Cláudia Maria Valete-Rosalino
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

2.  Effects of Forward- and Emitted-Pressure Calibrations on the Variability of Otoacoustic Emission Measurements Across Repeated Probe Fits.

Authors:  Tom Maxim; Christopher A Shera; Karolina K Charaziak; Carolina Abdala
Journal:  Ear Hear       Date:  2019 Nov/Dec       Impact factor: 3.570

3.  Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study.

Authors:  Gökçe Simsek; Burak Mustafa Taş; Nuray Bayar Muluk; Musa Azman; Rahmi Kılıç
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-09-17       Impact factor: 2.503

4.  Swept-tone stimulus-frequency otoacoustic emissions: Normative data and methodological considerations.

Authors:  Carolina Abdala; Yeini C Guardia; Christopher A Shera
Journal:  J Acoust Soc Am       Date:  2018-01       Impact factor: 1.840

5.  Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring.

Authors:  Dawn Konrad-Martin; Kristin Knight; Garnett P McMillan; Laura E Dreisbach; Elsa Nelson; Marilyn Dille
Journal:  Ear Hear       Date:  2020 Mar/Apr       Impact factor: 3.570

6.  Air-Conducted Vestibular Evoked Myogenic Potential Testing in Children, Adolescents, and Young Adults: Thresholds, Frequency Tuning, and Effects of Sound Exposure.

Authors:  Amanda I Rodriguez; Megan L A Thomas; Kristen L Janky
Journal:  Ear Hear       Date:  2019 Jan/Feb       Impact factor: 3.570

7.  Assessing Sensorineural Hearing Loss Using Various Transient-Evoked Otoacoustic Emission Stimulus Conditions.

Authors:  Daniel B Putterman; Douglas H Keefe; Lisa L Hunter; Angela C Garinis; Denis F Fitzpatrick; Garnett P McMillan; M Patrick Feeney
Journal:  Ear Hear       Date:  2017 Jul/Aug       Impact factor: 3.570

8.  GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs.

Authors:  Barna Budai; Péter Prekopp; László Noszek; Erika R Kovács; Márta Szőnyi; Dániel J Erdélyi; Krisztina Bíró; Lajos Géczi
Journal:  J Mol Med (Berl)       Date:  2020-05-20       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.